Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of May 2017 for Cellect Biotechnology Ltd., a foreign private issuer headquartered in Kfar Saba, Israel. The filing documents the outcome of an extraordinary meeting of shareholders, ADS holders, and Series-1 Stock Option holders convened on May 9, 2017.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance actions rather than financial performance data.
Material Changes
There are no material financial changes reported in this document. The primary event is the successful passage of all agenda items proposed for the extraordinary meetings held on May 9, 2017, as originally described in a prior Form 6-K filed on April 4, 2017.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, or contingencies. It notes that this report is incorporated by reference into the company's registration statement on Form S-8 (Registration No. 333-214817).
Key Facts for Investor Verification
- Shareholders and option holders approved all agenda items at the May 9, 2017, extraordinary meetings.
- The specific details of the approved agenda items are located in Exhibit 99.1 of the Form 6-K filed on April 4, 2017.
- This filing serves to update the Form S-8 registration statement regarding the approval of equity-related matters.
- No financial performance data is included in this specific filing.